Supercritical carbon dioxide tissue processing methods

Patent metadata

Field	Value
Publication number	US-2016008409-A1
Application number	US-201514794354-A
Country	US
Kind code	A1
Filing date	Jul 8, 2015
Priority date	Jul 9, 2014
Publication date	Jan 14, 2016
Grant date	—

Abstract

Embodiments of the present invention may include a method for improving handling characteristics of an amnion tissue. The method may include providing the amnion tissue from a human donor. Furthermore, the method may include exposing the amnion tissue to supercritical carbon dioxide to form an exposed amnion tissue. The exposed amnion tissue may have a higher ultimate tensile strength and elastic modulus than the amnion tissue before the exposure.

First claim

1 . A method for improving handling characteristics of an amnion tissue, comprising:
providing the amnion tissue from a human donor; and exposing the amnion tissue to supercritical carbon dioxide to form an exposed amnion tissue, wherein the exposed amnion tissue has a higher ultimate tensile strength than the amnion tissue before exposure.

2 . The method of claim 1 , wherein the exposed amnion tissue has an ultimate tensile strength greater than 25 kPa.

3 . The method of claim 1 , wherein the exposed amnion tissue has an elastic modulus greater than 100 kPa.

4 . The method of claim 1 , wherein exposing the amnion tissue comprises exposing the amnion tissue to supercritical carbon dioxide at a temperature from 32° C. to 38° C.

5 . The method of claim 1 , wherein exposing the amnion tissue comprises exposing the soft tissue to supercritical carbon dioxide at a temperature of 35° C.

6 . The method of claim 1 , wherein exposing the amnion tissue comprises exposing the amnion tissue to supercritical carbon dioxide for 1.5 to 4.5 hours.

7 . The method of claim 1 , wherein exposing the amnion tissue comprises exposing the amnion tissue to supercritical carbon dioxide for 3 hours.

8 . The method of claim 1 , wherein exposing the amnion tissue comprises exposing the amnion tissue to supercritical carbon dioxide at a pressure from 1,350 to 1,475 psi.

9 . The method of claim 1 , wherein the method further comprises sterilizing the amnion tissue without supercritical carbon dioxide.

10 . The method of claim 1 , wherein the exposed amnion tissue is less likely to tear than the amnion tissue before exposure.

11 . The method of claim 1 , wherein exposing the amnion tissue to the supercritical carbon dioxide comprises exposing the amnion tissue to additives.

12 . The method of claim 11 , wherein the additives comprise peracetic acid, hydrogen peroxide, or ethanol.

13 . The method of claim 11 , wherein exposing the amnion tissue comprises exposing the amnion tissue to a total volume of supercritical carbon dioxide and the volume of additives is greater than or equal to 0.001% the total volume of supercritical carbon dioxide.

14 . A method for treating a patient having a medical condition, comprising:
providing an amnion tissue from a human donor; exposing the amnion tissue to a supercritical carbon dioxide to form an exposed amniotic tissue; and administering the exposed amnion tissue to the patient.

15 . The method of claim 14 , wherein exposing the amnion tissue comprises exposing the amnion tissue to supercritical carbon dioxide at a temperature between 32° C. and 38° C.

16 . The method of claim 14 , wherein exposing the amnion tissue comprises exposing the amnion tissue to supercritical carbon dioxide at a temperature of 35° C.

17 . The method of claim 14 , wherein exposing the amnion tissue comprises exposing the amnion tissue to supercritical carbon dioxide for between 1.5 and 4.5 hours.

18 . The method of claim 14 , wherein exposing the amnion tissue comprises exposing the amnion tissue to supercritical carbon dioxide for 3 hours.

19 . The method of claim 14 , wherein exposing the amnion tissue comprises exposing the amnion tissue to supercritical carbon dioxide at a pressure between 1,350 and 1,475 psi.

20 . The method of claim 14 , wherein the method further comprises sterilizing the amnion tissue without supercritical carbon dioxide.

21 . The method of claim 14 , wherein the exposed amnion tissue is less likely to tear than the amnion tissue before exposure.

22 . The method of claim 14 , wherein exposing the amnion tissue to the supercritical carbon dioxide comprises exposing the amnion tissue to additives.

23 . The method of claim 22 , wherein the additives comprise peracetic acid, hydrogen peroxide, or ethanol.

24 . The method of claim 22 , wherein exposing the amnion tissue comprises exposing the amnion tissue to a total volume of supercritical carbon dioxide and the volume of additives is greater than or equal to 0.001% the total volume of supercritical carbon dioxide.

25 . An amnion tissue composition, comprising amnion tissue, wherein:
the amnion tissue has been treated with a supercritical carbon dioxide, and the amnion tissue composition has a higher ultimate tensile strength greater than amnion tissue not treated with the supercritical carbon dioxide.

26 . The composition of claim 25 , wherein the amnion tissue comprises additives.

27 . The composition of claim 26 , wherein the additives comprise peracetic acid, hydrogen peroxide, or ethanol.

28 . The composition of claim 25 , wherein the amnion tissue has an ultimate tensile strength greater than 25 kPa.

29 . The composition of claim 25 , wherein the amnion tissue has a higher elastic modulus than amnion tissue not treated with the supercritical carbon dioxide.

30 . The method of claim 14 , wherein treating the patient comprises preventing adhesions.

31 . The method of claim 14 , wherein administering the exposed amnion tissue to the patient comprises administering the exposed amnion tissue to a wound, a burn, a tendon, a rotator cuff, a hernia, a tissue disrupted during surgical repair, a meniscus, a nerve, a soft tissue, or a spine.

32 . The method of claim 14 , wherein the medical condition comprises tarsal tunnel syndrome, illiotibial band stenosis, phantom pain, a damaged meniscus, peripheral nerve damage, or peripheral nerve injury.

Assignees

• Allosource

Inventors

• Joslyn Arthur
• Walden Timothy

Classifications

• A61K35/50 Primary

  Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells · CPC title

• C12N5/0605

  Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly · CPC title

• C12N2500/02

  Atmosphere, e.g. low oxygen conditions · CPC title